PMID- 34182129
OWN - NLM
STAT- MEDLINE
DCOM- 20220209
LR  - 20220209
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 170
DP  - 2021 Aug
TI  - Hypoxia-inducible factor-1: Regulatory mechanisms and drug development in stroke.
PG  - 105742
LID - S1043-6618(21)00326-1 [pii]
LID - 10.1016/j.phrs.2021.105742 [doi]
AB  - Stroke is an acute cerebrovascular disease caused by sudden rupture of blood 
      vessels in the brain or blockage of blood vessels, which has now become one of 
      the main causes of adult death. During stroke, hypoxia-inducible factor-1 
      (HIF-1), as an important regulator under hypoxia conditions, is involved in the 
      pathological process of stroke by regulating multi-pathways, such as glucose 
      metabolism, angiogenesis, erythropoiesis, cell survival. However, the roles of 
      HIF-1 in stroke are still controversial, which are related with ischemic time and 
      degree of ischemia. The regulatory mechanisms of HIF-1 in stroke include 
      inflammation, autophagy, oxidative stress, apoptosis and energy metabolism. The 
      potential drugs targeting HIF-1 have attracted more attention, such as HIF-1 
      inhibitors, HIF-1 stabilizers and natural products. Based on the role of HIF-1 in 
      stroke, HIF-1 is expected to be a potential target for stroke treatment. 
      Resolving when and what interventions for HIF-1 to take during stroke will 
      provide novel strategies for stroke treatment.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Pan, Zirong
AU  - Pan Z
AD  - Beijing Key Laboratory of Drug Target Identification and Drug Screening, 
      Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union 
      Medical College, Beijing 100050, PR China.
FAU - Ma, Guodong
AU  - Ma G
AD  - Beijing Key Laboratory of Drug Target Identification and Drug Screening, 
      Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union 
      Medical College, Beijing 100050, PR China.
FAU - Kong, Linglei
AU  - Kong L
AD  - Beijing Key Laboratory of Drug Target Identification and Drug Screening, 
      Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union 
      Medical College, Beijing 100050, PR China. Electronic address: 
      konglinglei@imm.ac.cn.
FAU - Du, Guanhua
AU  - Du G
AD  - Beijing Key Laboratory of Drug Target Identification and Drug Screening, 
      Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union 
      Medical College, Beijing 100050, PR China. Electronic address: dugh@imm.ac.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210625
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Hypoxia-Inducible Factor 1)
SB  - IM
MH  - Animals
MH  - Brain/*drug effects/metabolism/physiopathology
MH  - *Drug Design
MH  - *Drug Development
MH  - Humans
MH  - Hypoxia-Inducible Factor 1/*antagonists & inhibitors/metabolism
MH  - *Molecular Targeted Therapy
MH  - Protein Stability
MH  - Signal Transduction
MH  - Stroke/*drug therapy/metabolism/physiopathology
OTO - NOTNLM
OT  - Drug development
OT  - Hypoxia-inducible factor 1
OT  - Stroke
EDAT- 2021/06/29 06:00
MHDA- 2022/02/10 06:00
CRDT- 2021/06/28 20:15
PHST- 2021/05/05 00:00 [received]
PHST- 2021/06/13 00:00 [revised]
PHST- 2021/06/23 00:00 [accepted]
PHST- 2021/06/29 06:00 [pubmed]
PHST- 2022/02/10 06:00 [medline]
PHST- 2021/06/28 20:15 [entrez]
AID - S1043-6618(21)00326-1 [pii]
AID - 10.1016/j.phrs.2021.105742 [doi]
PST - ppublish
SO  - Pharmacol Res. 2021 Aug;170:105742. doi: 10.1016/j.phrs.2021.105742. Epub 2021 
      Jun 25.